top of page


  • AutorenbildJuergen Mairhofer

enGenes Biotech supports Vienna-based initiative to establish serology test for Covid-19

Vienna, Austria: – Recombinant proteins specialist CDMO enGenes Biotech GmbH (enGenes) has entered a new project in collaboration with Vienna’s University of Natural Resources and Life Sciences (BOKU) and other partners to produce SARS CoV-2 antigens and establish a serology test to determine coronavirus SARS-Cov-2 antibody titers.

The research project could play a significant role in developing a cost-effective vaccine and advanced antibody testing regimes to combat the global pandemic viral infection.

Autoimmune response

The asymptomatic Covid-19 group do not show the typical symptoms of COVID-19, including high temperature, dry cough, loss of taste/smell or fatigue. Nevertheless, it is believed this group eventually develops an immune response that protects them against reinfection.

Austrian researcher Prof. Florian Krammer, Scientific Advisor to enGenes Biotech, has developed a test protocol for the first non-commercial antibody test at the Icahn School of Medicine at Mount Sinai, New York.

As a BOKU spin-off, enGenes Biotech is supporting the project in establishing serological tests, drawing on its recombinant protein expertise and applying its highly efficient growth-decoupled enGenes-eXpress expression in Escherichia coli platform to manufacture top-quality recombinant virus proteins and plasmid DNA as required for establishing these tests.


bottom of page